PanTHer Therapeutics Closes $5.4M in Series A Funding


PanTher Therapeutics, a Cambridge MA-based company advancing treatments for solid tumors, raised $5.4M in Series A funding.

The round was led by Catalyst Health Ventures (CHV), with participation from Angel Physicians Fund (APF) and other notable investors. In conjunction with the funding, Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, joined PanTher’s board of directors.

The company intends to use the funds to expands its development efforts and to initiate first clinical trial of novel localized treatment of pancreatic cancer. Proceeds from the funding will go toward the first-in-human clinical trial.

Led by Laura Indolfi, CEO and Co-Founder, PanTher is an oncology company advancing new treatments for solid tumors through direct, localized, and sustained delivery of proven and novel therapeutic agents. The company’s proprietary platform is based on technology that was developed at the Massachusetts Institute of Technology (MIT) and was subsequently in-licensed by PanTher.

The company’s lead candidate is designed to control tumor progression in pancreatic cancer and is integrated into a commonly used, minimally invasive staging procedure. PanTher’s platform technology can be adapted to treat additional solid tumor indications.